Please remember this is an event for healthcare professionals only, and that photos may not be taken and/or shared externally on platforms such as social medias.
We may send you post-meeting materials and ask you to complete a survey following the meeting.
The information you provide will be used by Gilead and its appointed agency, NexGen Healthcare Communications Ltd, for the purpose of registering you at this promotional meeting. You can find more information about how Gilead processes personal information here: https://www.gilead.com/pdf/privacy-statement
This workshop will include materials and discussion of licensed products and is organised and fully funded by Kite, a Gilead Company, through Gilead Sciences Europe Ltd (“Gilead”).
Prescribing information and adverse event reporting
Yescarta®▼ (axicabtagene ciloleucel) prescribing information for Great Britain can be found here: https://www.emcpi.com/pi/35345
Yescarta prescribing information for Northern Ireland and Ireland can be found here: https://www.emcpi.com/pi/ni/383
Yescarta prescribing information for Germany can be found here: https://www.gileadpro.de/-/media/project/gileadpro/ germany/product-catalog/yescarta/fachinformation/fachinformation_yescarta_infusionsdispersion_gilead.pdf
Registration conditions may differ from one country to another, please refer to your local SmPC. EMA product information for Yescarta can be found here: https://www.ema.europa.eu/documents/product-information/yescarta-epar-product-information_en.pdf
Yescarta, the Yescarta logo, KITE and the KITE logo are registered trademarks of Kite, a Gilead Company. (C) 2024 Gilead Sciences, Inc. All rights reserved.
▼Yescarta is subject to additional monitoring.
All countries
Healthcare professionals should report any adverse event via their national reporting systems. Reporting forms and information for your country of residence can be found here: www.gilead.com/utility/contact/report-an-adverse-event. Adverse events should also be reported to Gilead via safety_FC@gilead.com or +44 (0) 1223 897500.
UK and Ireland
Adverse events should be reported. For Great Britain & Northern Ireland, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
Adverse events should be reported. For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to safety_FC@gilead.com or +44 (0) 1223 897500.
CAR T, chimeric antigen receptor T-cell; DLBCL, diffuse large B-cell lymphoma; R/R, relapsed/refractory.
IHQ-YES-0649 | Date of Preparation: March 2024